Roivant Sciences (ROIV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 11. Analyst David Risinger from Leerink Partners reiterated a Buy rating on the stock and has a $17.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Risinger has given his Buy rating due to a combination of factors that highlight Roivant Sciences’ promising future. The firm is expected to make significant progress in 2025 with key pipeline developments and corporate updates that could positively impact the stock. Notably, Roivant has increased its ownership in IMVT, which is set to release pivotal data from its FcRn program soon. These results will be crucial for the advancement of their next-generation FcRn program, IMVT-1402, which is projected to expand into multiple studies by early 2026.
Additionally, there is potential in brepocitinib’s application for cutaneous sarcoidosis, a condition with no existing approved treatments for the 30,000 to 50,000 patients in the U.S. The company is optimistic due to compelling preliminary data and plans to conduct a Phase 2 study to further explore this opportunity. This combination of strategic investments, pipeline advancements, and new therapeutic opportunities underpins the confidence in Roivant’s stock’s potential growth.
In another report released on February 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
Based on the recent corporate insider activity of 113 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ROIV in relation to earlier this year.